Press Releases

Jan 15, 2014

Meridian Bioscience Provides Preliminary First Quarter Operating Results, Reaffirms Guidance for Fiscal 2014 and Comments on the Business

Jan 14, 2014

Bioline Expands into Singapore

Jan 10, 2014

Meridian Bioscience Granted Special 510(k) Clearance for TRU FLU® to Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim

Nov 14, 2013

PCR from Whole Blood, Simplified

Nov 07, 2013

Meridian Bioscience Reports Record Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, Announces Increased Regular Cash Dividend Rate for Fiscal 2014, and Reaffirms Fiscal 2014 Guidance

Oct 31, 2013

Meridian Life Science Awarded SBIR by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine

Sep 09, 2013

Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2014 and Reaffirms Fiscal 2013 Guidance

Jul 30, 2013

Meridian Life Science® Successfully Manufactures Influenza Challenge Stock for Immune Targeting Systems

Jul 25, 2013

Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance

Jul 02, 2013

Bioline Launches the MyTaq™ Extract-PCR Kit, Single Tube Extraction of PCR-Ready DNA from Mammalian Tissues

Jun 10, 2013

Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Mycoplasma

Apr 25, 2013

Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance

Mar 28, 2013

Meridian Bioscience Recognized by Forbes as One of America’s 100 Most Trustworthy Companies

Mar 18, 2013

Meridian Bioscience Announces illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests Categorized “Moderate Complexity” by FDA

Feb 06, 2013

Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation

Jan 23, 2013

Meridian Bioscience Reports First Quarter 2013 Operating Results and Reaffirms Fiscal 2013 Guidance

Dec 13, 2012

Meridian Bioscience Successfully Completes Beta Trials for Two New illumigene® Tests

Dec 04, 2012

Meridian Bioscience, Inc. Declares Regular Quarterly Dividend and Accelerates Payment Date to December 24, 2012

Nov 28, 2012

SensiFAST™ Genotyping Kit Exceed the Limit

Nov 08, 2012

Meridian Bioscience Reports Fourth Quarter and Full-Year 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance

Innerpage

Meridian Bioscience Provides Preliminary First Quarter Operating Results, Reaffirms Guidance for Fiscal 2014 and Comments on the Business

Bioline Expands into Singapore

Meridian Bioscience Granted Special 510(k) Clearance for TRU FLU® to Add Avian H7N9 Influenza A Virus Analytical Sensitivity Claim

PCR from Whole Blood, Simplified

Meridian Bioscience Reports Record Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, Announces Increased Regular Cash Dividend Rate for Fiscal 2014, and Reaffirms Fiscal 2014 Guidance

Meridian Life Science Awarded SBIR by Centers for Disease Control and Prevention to Develop Rotavirus Vaccine

Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2014 and Reaffirms Fiscal 2013 Guidance

Meridian Life Science® Successfully Manufactures Influenza Challenge Stock for Immune Targeting Systems

Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance

Bioline Launches the MyTaq™ Extract-PCR Kit, Single Tube Extraction of PCR-Ready DNA from Mammalian Tissues

Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® Mycoplasma

Meridian Bioscience Reports Second Quarter and Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance

Meridian Bioscience Recognized by Forbes as One of America’s 100 Most Trustworthy Companies

Meridian Bioscience Announces illumigene® Group A Streptococcus and illumigene® Group B Streptococcus Tests Categorized “Moderate Complexity” by FDA

Bioline Launches ISOLATE II, a Precious Find for DNA and RNA Isolation

Meridian Bioscience Reports First Quarter 2013 Operating Results and Reaffirms Fiscal 2013 Guidance

Meridian Bioscience Successfully Completes Beta Trials for Two New illumigene® Tests

Meridian Bioscience, Inc. Declares Regular Quarterly Dividend and Accelerates Payment Date to December 24, 2012

SensiFAST™ Genotyping Kit Exceed the Limit

Meridian Bioscience Reports Fourth Quarter and Full-Year 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance